Puerarin Attenuates Cycloheximide-Induced Oxidative Damage and Memory-Consolidation Impairment in Rats

• Published in: Journal of integrative neuroscience Vol. 23; no. 1; p. 17
• Main Authors: Wu, Kuo-Jen, Lien, Jin-Cherng, Wu, Chi-Rei
• Format: Journal Article
• Language: English
• Published: Singapore IMR Press 16.01.2024
• Subjects: Animals; Antioxidants; cycloheximide; Cycloheximide - adverse effects; Isoflavones; Memory Consolidation; Memory Disorders - chemically induced; Memory Disorders - drug therapy; Neurotransmitter Agents - adverse effects; neurotransmitters; oxidative damage; Oxidative Stress; passive avoidance task; puerarin; Rats; cycloheximide; oxidative damage; puerarin; neurotransmitters; passive avoidance task
• ISSN: 0219-6352
• DOI: 10.31083/j.jin2301017

Cycloheximide (CXM), an antifungal antibiotic, causes impaired memory consolidation as a side effect partially by disturbing the activities of the central catecholaminergic and cholinergic system. Some reports indicated that puerarin prevented memory impairment in various models in rodents. However, the protective effects of puerarin on the side effects of cycloheximide for memory consolidation impairment have not yet been investigated. The protective effects of puerarin on CXM-induced memory-consolidation impairment, and memory impairment produced by central administration of AF64A neurotoxin, were investigated using a passive avoidance task in rats. A combination of transmitter receptor agonists and antagonists was used to explore the effects of puerarin on nervous system function. The activity of antioxidant defense systems and neurotransmitter systems in the prefrontal cortex and hippocampus were assayed. Systemic (25 and 50 mg/kg, i.p.) or central (5 and 10 µg/brain, i.c.v.) administration of puerarin attenuated CXM-induced memory-consolidation impairment produced by 1.5 mg/kg CXM (s.c.) in rats. The improvements produced by 50 mg/kg puerarin were blocked by cholinergic antagonists, a 5-HT2 receptor agonist, and an adrenergic receptor antagonist. Puerarin (only at 50 mg/kg, i.p.) reversed the CXM-induced alterations of the levels of norepinephrine in the prefrontal cortex and the levels of monoamines in the hippocampus. Puerarin also increased antioxidant-defense-system activities in the prefrontal cortex and hippocampus, which had been decreased by CXM. We suggested that the attenuating effects of puerarin on CXM-induced memory-consolidation impairment may be due to decrease oxidative damage and the normalition of the neurotransmitter function in the prefrontal cortex and hippocampus.